液態切片在治療追蹤、腫瘤反應與預後的觀察型研究

Abstract

精準醫療在未來的醫療模式是不可或缺的一環。本研究主張：癌症患者接受液態切片後，針對腫瘤分子型態制訂其治療計劃，腫瘤反應與預後會較佳，也對後續治療追蹤其療效及復發是不錯的輔助工具，在未來液態切片市場有相當大的潛力。為檢證這樣的論點，本研究以檢驗液態切片的癌症患者為對象來探討這樣的預期。整個研究分二階段進行：首先，透過市場調查並加以臨床深度訪談的方式，了解液態切片對癌症病人的使用訂位及市場未來發展方向。 研究發現：(一) 研究結果發現臨床醫師挑選之病人族群使用液態切片基因測序，的確是可以輔助臨床使用符合病人的個人化醫治療，對於部分族群之腫瘤有明顯治療效果。(二) 針對部分化療耐受性較差、副作用敏感的病人，有利於找到適合標靶用藥，減少試藥帶來的副作用及爭取治療時間。(三) 臨床專家認為適合使用液態切片的族群，經分析病人數、市場聚焦於此相當具有潛力。

Precision medicine is an indispensable part of future medical service.This study advocated that a treatment plan in target of its tumor molecular type must be developed based on the cancer patient’s liquid biopsy to yield a better response and prognosis. It would serve as a better supplement to follow up therapies, by tracking the efficacy and tumor recurrence. The liquid biopsy does show considerable potential in the future market. In order to verify the argument,this study would explore such expectation in cancer patients who had liquid biopsy exami nation. The entire research was conducted in two phases: First, market survey with in depth clinical interview was performed to understand the product positioning of liquid biopsy for cancer patients and its possible future direction in the market.The study found: 1) The genetic sequencing of liquid biopsy for patients selected by clinical physicians could indeed help in customization of individual therapy and showed significant improvement in therapeutic outcome for some tumor cases. 2) For patients with poor tolerance to chemotherapy who might even experience some side effects, it benefited them in finding the most appropriate target drugs to minimize any adverse reactions and even maximize the chance of getting treatment as early as possible. 3) Clinical experts believed that liquid biopsy is not only suitable for some people, but its ability to analyze the patient cluster and direct marketing focus shows great potential.